SCHEMBL19082959

SCHEMBL19082959

Cc1nc(NCc2nccnc2CO)c2cc[nH]c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
DYRK1A Q13627 3/20 0.35
DYRK2 Q92630 3/20 0.35
DYRK1B Q9Y463 3/20 0.35
CLK1 P49759 2/20 0.35
DYRK3 O43781 1/20 0.35
DYRK4 Q9NR20 1/20 0.35
CLK2 P49760 1/20 0.34
AURKB Q96GD4 1/20 0.34
CLK4 Q9HAZ1 1/20 0.34
NUDT1 P36639 2/20 0.34
HDAC6 Q9UBN7 1/20 0.34
SYK P43405 1/20 0.34
PTK2 Q05397 1/20 0.33
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19082969 0.87 CLK2 (0.40) LMNATSHRHTTDYRK1ADYRK2
SCHEMBL19082960 0.80 NUDT1 (0.36) DYRK1ADYRK1BCLK2AURKBCLK4
SCHEMBL29829728 0.80 CYP1A2 (0.37) LMNATSHRHTT
SCHEMBL19065260 0.80 CYP1A2 (0.37) LMNATSHRHTT
SCHEMBL19082950 0.80 TSHR (0.39) LMNATSHRHTTDYRK1ACLK2
SCHEMBL17017331 0.78 DYRK1A (0.34) DYRK1ADYRK2DYRK1BCLK1DYRK3
SCHEMBL19082962 0.77 CLK2 (0.39) LMNATSHRHTTDYRK1BCLK1
SCHEMBL19082945 0.77 LMNA (0.44) LMNATSHRHTTDYRK1ACLK2
SCHEMBL19082947 0.76 LMNA (0.36) LMNATSHRHTTDYRK1ACLK2
Rolodine SCHEMBL121916 0.74 NPY5R (0.49) LMNADYRK1ADYRK2DYRK1BPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170190704-A1 COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE Mitokinin, LLC (US) 2017-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190704-A1 COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE NLN, HAGH, MT-ND2 LMNA 1132/4885TSHR 4608/4885HTT 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.